BR112015004469A2 - sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares - Google Patents

sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares

Info

Publication number
BR112015004469A2
BR112015004469A2 BR112015004469A BR112015004469A BR112015004469A2 BR 112015004469 A2 BR112015004469 A2 BR 112015004469A2 BR 112015004469 A BR112015004469 A BR 112015004469A BR 112015004469 A BR112015004469 A BR 112015004469A BR 112015004469 A2 BR112015004469 A2 BR 112015004469A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
sirna
prevention
treatment
Prior art date
Application number
BR112015004469A
Other languages
English (en)
Other versions
BR112015004469B8 (pt
BR112015004469B1 (pt
Inventor
Isabel Jimenez Anton Ana
Ruz Palomar Veronica
Gonzalez Fajardo Victoria
Original Assignee
Sylentis Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sau filed Critical Sylentis Sau
Publication of BR112015004469A2 publication Critical patent/BR112015004469A2/pt
Publication of BR112015004469B1 publication Critical patent/BR112015004469B1/pt
Publication of BR112015004469B8 publication Critical patent/BR112015004469B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo da patente de invenção para: "sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares". a invenção se refere a métodos e composições para o tratamento e/ou prevenção de condições oculares relacionadas a altos níveis de expressão e/ou atividade do receptor vaniloide-1 (trpv).
BR112015004469A 2012-09-05 2013-09-04 Kit medicinal para administração de um sirna BR112015004469B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1215857.2A GB201215857D0 (en) 2012-09-05 2012-09-05 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
GB1215857.2 2012-09-05
PCT/EP2013/068245 WO2014037377A1 (en) 2012-09-05 2013-09-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (3)

Publication Number Publication Date
BR112015004469A2 true BR112015004469A2 (pt) 2017-08-08
BR112015004469B1 BR112015004469B1 (pt) 2022-11-16
BR112015004469B8 BR112015004469B8 (pt) 2022-12-06

Family

ID=47136985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015004469A BR112015004469B8 (pt) 2012-09-05 2013-09-04 Kit medicinal para administração de um sirna

Country Status (30)

Country Link
US (1) US9808479B2 (pt)
EP (1) EP2893019B1 (pt)
JP (2) JP2015529210A (pt)
KR (1) KR102136539B1 (pt)
CN (2) CN108354944A (pt)
AU (1) AU2013311781B2 (pt)
BR (1) BR112015004469B8 (pt)
CA (1) CA2883040C (pt)
CL (1) CL2015000537A1 (pt)
CY (1) CY1121000T1 (pt)
DK (1) DK2893019T3 (pt)
EC (1) ECSP15009391A (pt)
ES (1) ES2685346T3 (pt)
GB (1) GB201215857D0 (pt)
HK (1) HK1212377A1 (pt)
HR (1) HRP20181079T1 (pt)
HU (1) HUE040096T2 (pt)
IL (1) IL237389B (pt)
IN (1) IN2015DN02501A (pt)
LT (1) LT2893019T (pt)
MX (1) MX362854B (pt)
PE (1) PE20150619A1 (pt)
PL (1) PL2893019T3 (pt)
PT (1) PT2893019T (pt)
RS (1) RS57620B1 (pt)
RU (1) RU2663100C2 (pt)
SG (1) SG11201501386TA (pt)
SI (1) SI2893019T1 (pt)
WO (1) WO2014037377A1 (pt)
ZA (1) ZA201501494B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003520A1 (en) 2011-06-30 2013-01-03 Arrowhead Research Corporation Compositions and methods for inhibiting gene expression of hepatitis b virus
EP3332007A4 (en) 2015-08-07 2019-07-17 Arrowhead Pharmaceuticals, Inc. RNA INTERFERENCE THERAPY FOR HEPATITIS B VIRUS INFECTION
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
KR20210129677A (ko) 2019-02-15 2021-10-28 노파르티스 아게 안구 표면 통증의 치료 방법
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
EP4043014A4 (en) * 2019-10-04 2023-10-11 Senju Pharmaceutical Co., Ltd. PHARMACEUTICAL MEDICINAL PRODUCT CONTAINING HETEROCYCLIDE ACETAMIDE DERIVATIVE

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
ES2728168T3 (es) 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
US20020165158A1 (en) 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
EP1495121A2 (en) 2002-04-18 2005-01-12 Lynkeus Biotech GmbH Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US20040115641A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
CA2493564A1 (en) 2002-07-24 2004-01-29 Immusol, Inc. Novel sirna libraries and their production and use
WO2004009796A2 (en) 2002-07-24 2004-01-29 Immusol Incorporated Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker
BRPI0313202A8 (pt) 2002-08-05 2016-08-16 Atugen Ag Formas adicionais para interferir com as moléculas de rna
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
AU2003282877B9 (en) 2002-09-25 2011-05-12 University Of Massachusetts In Vivo gene silencing by chemically modified and stable siRNA
US7521431B2 (en) 2002-11-01 2009-04-21 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2284266B1 (en) 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
WO2004099372A2 (en) 2003-05-01 2004-11-18 University Of Florida Anti-scarring ribozymes and methods
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
EP1636342A4 (en) 2003-06-20 2008-10-08 Isis Pharmaceuticals Inc OLIGOMERIC COMPOUNDS FOR GENE MODULATION
EP1685109A2 (en) 2003-10-07 2006-08-02 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20050039573A (ko) 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
US20050208658A1 (en) 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
DK1699924T3 (da) * 2003-12-03 2019-10-21 Ocunexus Therapeutics Inc Connexin 43-målrettede hæmmende forbindelser og fremgangsmåder til anvendelse deraf i behandling af hornhindetraume
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005076998A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
US7947659B2 (en) 2004-03-12 2011-05-24 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
AU2005272816B2 (en) 2004-08-10 2011-08-11 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
PL1781787T3 (pl) 2004-08-23 2018-01-31 Sylentis Sau Leczenie zaburzeń oka charakteryzowanych przez podwyższone ciśnienie wewnątrzgałkowe przy użyciu siRNA
TW200639252A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
AU2006223131A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
GB0521351D0 (en) 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
US20080051361A1 (en) * 2006-08-24 2008-02-28 Alcon Manufacturing, Ltd. Rnai-mediated inhibition of gremlin for treatment of iop-related conditions
WO2009023025A1 (en) 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
CN201337650Y (zh) * 2009-01-06 2009-11-04 河北科技大学 一次性药用单剂量液体容器
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Also Published As

Publication number Publication date
HK1212377A1 (en) 2016-06-10
RU2663100C2 (ru) 2018-08-01
CA2883040C (en) 2023-01-17
JP2015529210A (ja) 2015-10-05
SG11201501386TA (en) 2015-03-30
AU2013311781B2 (en) 2018-10-18
CA2883040A1 (en) 2014-03-13
IL237389A0 (en) 2015-04-30
ECSP15009391A (es) 2015-12-31
US9808479B2 (en) 2017-11-07
CY1121000T1 (el) 2019-12-11
PE20150619A1 (es) 2015-05-11
CN108354944A (zh) 2018-08-03
LT2893019T (lt) 2018-08-10
MX2015002802A (es) 2015-05-15
SI2893019T1 (sl) 2018-09-28
WO2014037377A1 (en) 2014-03-13
AU2013311781A1 (en) 2015-03-12
BR112015004469B8 (pt) 2022-12-06
US20150224131A1 (en) 2015-08-13
BR112015004469B1 (pt) 2022-11-16
RS57620B1 (sr) 2018-11-30
IL237389B (en) 2019-01-31
JP6742362B2 (ja) 2020-08-19
EP2893019A1 (en) 2015-07-15
HUE040096T2 (hu) 2019-02-28
ES2685346T3 (es) 2018-10-08
GB201215857D0 (en) 2012-10-24
KR20150047513A (ko) 2015-05-04
DK2893019T3 (en) 2018-09-03
CL2015000537A1 (es) 2015-07-10
CN104640988A (zh) 2015-05-20
PT2893019T (pt) 2018-10-19
ZA201501494B (en) 2016-01-27
IN2015DN02501A (pt) 2015-09-11
PL2893019T3 (pl) 2018-12-31
JP2018138596A (ja) 2018-09-06
RU2015112121A (ru) 2016-10-27
KR102136539B1 (ko) 2020-07-23
MX362854B (es) 2019-02-20
EP2893019B1 (en) 2018-05-30
HRP20181079T1 (hr) 2018-09-07

Similar Documents

Publication Publication Date Title
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
BR112015007985A8 (pt) uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições
MY169328A (en) Compositions for the treatment of dry eye
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MY171920A (en) Prevention and treatment of ocular conditions
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112015004469A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
NZ704247A (en) Compositions and treatment for eye diseases and disorders
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
EP2910247A4 (en) COMPOSITIONS FOR PREVENTING OR TREATING ALLERGIC SKIN DISORDERS CONTAINING GPCR19 AGENTS AS ACTIVE INGREDIENTS
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2014011218A (es) Uso de agentes tensoactivos anfotericos para la prevencion y tratamiento de biopeliculas vaginales patogenas en infecciones vaginales.
GB201115977D0 (en) Neurodevelopmental disorders
MX2014006662A (es) Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2013, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2706 DE 16/11/2022 QUANTO AO ENDERECO POR ERRO MATERIAL DE TITULAR.